Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice

Leuk Lymphoma. 2012 May;53(5):982-4. doi: 10.3109/10428194.2011.643407. Epub 2012 Jan 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived
  • Chemoprevention / methods
  • Cyclophosphamide
  • Doxorubicin
  • Drug Administration Schedule
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Prednisolone
  • Premedication / methods
  • Rituximab
  • Vincristine

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Granulocyte Colony-Stimulating Factor
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone